Abstract
Background
Gastric cancer (GC) is a deadly malignancy worldwide. In the past, it has been shown that cellular signaling pathway alterations play a crucial role in the development of GC. In particular, deregulation of the PI3K/AKT/mTOR pathway seems to affect multiple GC functions including growth, proliferation, metabolism, motility and angiogenesis. Targeting alterations in this pathway by microRNAs (miRNAs) represents a potential therapeutic strategy, especially in inhibitor-resistant tumors. The objective of this study was to evaluate the expression of 3 pre-selected miRNAs, miR-101-2, miR-125b-2 and miR-451a, in a series of primary GC tissues and matched non-GC tissues and in several GC-derived cell lines, and to subsequently evaluate the functional role of these miRNAs.
Methods
Twenty-five primary GC samples, 25 matched non-GC samples and 3 GC-derived cell lines, i.e., AGS, MKN28 and MKN45, were included in this study. miRNA and target gene expression levels were assessed by quantitative RT-PCR and western blotting, respectively. Subsequently, cell viability, clone formation, cell death, migration and invasion assays were performed on AGS cells.
Results
miR-101-2, miR-125b-2 and miR-451a were found to be down-regulated in the primary GC tissues and the GC-derived cell lines tested. MiRNA mimic transfections significantly reduced cell viability and colony formation, increased cell death and reduced cell migration and invasion in AGS cells. We also found that exogenous expression of miR-101-2, miR-125b-2 and miR-451a decreased the expression of their putative targets MTOR, PIK3CB and TSC1, respectively.
Conclusions
Our expression analyses and in vitro functional assays suggest that miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in primary GCs as well as in GC-derived AGS cells.
Similar content being viewed by others
References
A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics. CA Cancer J. Clin. 61, 69–90 (2011)
A. Yousuf, M.Y. Bhat, A.A. Pandith, D. Afroze, N.P. Khan, K. Alam, P. Shah, M.A. Shah, S. Mudassar, A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, M.G.M.T. Gene, Silencing by promoter hypermethylation in gastric cancer in a high incidence area. Cell. Oncol. 37, 245–52 (2014)
V. Catalano, R. Labianca, G.D. Beretta, G. Gatta, F. de Braud, E. Van Cutsem, Gastric cancer. Crit. Rev. Oncol. Hematol. 71, 127–64 (2009)
H.H. Hartgrink, E.P.M. Jansen, N.C.T. van Grieken, C.J.H. van de Velde, Gastric cancer. Lancet 374, 477–490 (2009)
M. Labots, T.E. Buffart, J.C. Haan, N.C.T. van Grieken, M. Tijssen, C.J.H. van de Velde, H.I. Grabsch, B. Ylstra, B. Carvalho, R.J.A. Fijneman, H.M.W. Verheul, G.A. Meijer, High-level copy number gains of established and potential drug target genes in gastric cancer as a lead for treatment development and selection. Cell. Oncol. 37, 41–52 (2014)
B.J. Dicken, D.L. Bigam, C. Cass, J.R. Mackey, A.A. Joy, S.M. Hamilton, Gastric adenocarcinoma: review and considerations for future directions. Ann. Surg. 241, 27–39 (2005)
S.-E. Al-Batran, M. Ducreux, A. Ohtsu, mTOR as a therapeutic target in patients with gastric cancer. Int. J. Cancer 130, 491–6 (2012)
O. Tapia, I. Riquelme, P. Leal, A. Sandoval, S. Aedo, H. Weber, P. Letelier, E. Bellolio, M. Villaseca, P. Garcia, J.C. Roa, The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch. 465, 25–33 (2014)
The Cancer Genome Atlas Research Network, Comprehensive Molecular Characterization of Gastric Adenocarcinoma. Nature. 513, 202–9 (2014)
E. Caron, S. Ghosh, Y. Matsuoka, D. Ashton-Beaucage, M. Therrien, S. Lemieux, C. Perreault, P.P. Roux, H. Kitano, A comprehensive map of the mTOR signaling network. Mol. Syst. Biol. 6, 453 (2010)
D. Morgensztern, H.L. McLeod, PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16, 797–803 (2005)
D.P. Bartel, MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–97 (2004)
Y. Wang, M. Li, W. Zang, Y. Ma, N. Wang, P. Li, T. Wang, G. Zhao, MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell. Oncol. 36, 385–94 (2013)
T.A. Farazi, J.I. Hoell, P. Morozov, T. Tuschl, MicroRNAs in human cancer. Adv. Exp. Med. Biol. 774, 1–20 (2013)
A. Esquela-Kerscher, F.J. Slack, Oncomirs - microRNAs with a role in cancer. Nat. Rev. Cancer 6, 259–69 (2006)
R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera, miRNAs in head and neck cancer revisited. Cell. Oncol. 36, 1–7 (2013)
C.M. Croce, G.A. Calin, miRNAs, cancer, and stem cell division. Cell 122, 6–7 (2005)
K.N. Ivey, D. Srivastava, MicroRNAs as regulators of differentiation and cell fate decisions. Cell Stem Cell 7, 36–41 (2010)
R. Garzon, M. Fabbri, A. Cimmino, G.A. Calin, C.M. Croce, MicroRNA expression and function in cancer. Trends Mol. Med. 12, 580–7 (2006)
W.C.S. Cho, OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 6, 60 (2007)
M. Fabbri, miRNAs as molecular biomarkers of cancer. Expert Rev. Mol. Diagn. 10, 435–44 (2010)
E. Chan, D.E. Prado, J.B. Weidhaas, Cancer microRNAs: from subtype profiling to predictors of response to therapy. Trends Mol. Med. 17, 235–43 (2011)
A. Strillacci, C. Griffoni, P. Sansone, P. Paterini, G. Piazzi, G. Lazzarini, E. Spisni, M.A. Pantaleo, G. Biasco, V. Tomasi, MiR-101 downregulation is involved in cyclooxygenase-2 overexpression in human colon cancer cells. Exp. Cell Res. 315, 1439–47 (2009)
R.B. Batchu, O. Gruzdyn, A.M. Qazi, D. Bouwman, S.A. Gruber, D.W. Weaver, MicroRNA-101 (miR-101) enhances chemosensitivity of pancreatic ductal adenocarcinoma (PDAC) cells by inhibition of MTOR signaling Via PRAS40. J. Surg. Res. 172, 233 (2012)
J. Buechner, E. Tømte, B.H. Haug, J.R. Henriksen, C. Løkke, T. Flægstad, C. Einvik, Tumour-suppressor microRNAs Let-7 and Mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br. J. Cancer 105, 296–303 (2011)
C.-W. Chiang, Y. Huang, K.-W. Leong, L.-C. Chen, H.-C. Chen, S.-J. Chen, C.-K. Chou, PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells. J. Biomed. Sci. 17, 35 (2010)
L. Liang, C.-M. Wong, Q. Ying, D.N.-Y. Fan, S. Huang, J. Ding, J. Yao, M. Yan, J. Li, M. Yao, I.O.-L. Ng, X. He, MicroRNA-125b suppressesed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. Hepatology 52, 1731–40 (2010)
L. Liu, H. Li, J. Li, H. Zhong, H. Zhang, J. Chen, T. Xiao, miR-125b suppresses the proliferation and migration of osteosarcoma cells through down-regulation of STAT3. Biochem. Biophys. Res. Commun. 416, 31–8 (2011)
G.K. Scott, A. Goga, D. Bhaumik, C.E. Berger, C.S. Sullivan, C.C. Benz, Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J. Biol. Chem. 282, 1479–86 (2007)
E. Bandres, N. Bitarte, F. Arias, J. Agorreta, P. Fortes, X. Agirre, R. Zarate, J.A. Diaz-Gonzalez, N. Ramirez, J.J. Sola, P. Jimenez, J. Rodriguez, J. Garcia-Foncillas, microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin. Cancer Res. 15, 2281–90 (2009)
Y. Nan, L. Han, A. Zhang, G. Wang, Z. Jia, Y. Yang, X. Yue, P. Pu, Y. Zhong, C. Kang, MiRNA-451 plays a role as tumor suppressor in human glioma cells. Brain Res. 1359, 14–21 (2010)
J. Godlewski, M.O. Nowicki, A. Bronisz, G. Nuovo, J. Palatini, M. De Lay, J. Van Brocklyn, M.C. Ostrowski, E.A. Chiocca, S.E. Lawler, MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol. Cell 37, 620–32 (2010)
H. Zhou, J.-M. Guo, Y.-R. Lou, X.-J. Zhang, F.-D. Zhong, Z. Jiang, J. Cheng, B.-X. Xiao, Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J. Mol. Med. (Berl.) 88, 709–17 (2010)
H.-J. Wang, H.-J. Ruan, X.-J. He, Y.-Y. Ma, X.-T. Jiang, Y.-J. Xia, Z.-Y. Ye, H.-Q. Tao, MicroRNA-101 is down-regulated in gastric cancer and involved in cell migration and invasion. Eur. J. Cancer 46, 2295–2303 (2010)
Z.-X. Yang, C.-Y. Lu, Y.-L. Yang, K.-F. Dou, K.-S. Tao, MicroRNA-125b expression in gastric adenocarcinoma and its effect on the proliferation of gastric cancer cells. Mol. Med. Rep. 7, 229–232 (2013)
Y. Cheng, L. Chen, X. Cao, S. Ha, X. Xia, Expression profiling and functional analysis of hsa-miR-125b and its target genes in drug-resistant cell line of human gastric cancer. Hereditas 36, 119–128 (2014)
J.G. Clohessy, M. Reschke, P.P. Pandolfi, Found in translation of mTOR signaling. Cell Res. 22, 1315–8 (2012)
I. Beuvink, A. Boulay, S. Fumagalli, F. Zilbermann, S. Ruetz, T. O’Reilly, F. Natt, J. Hall, H.A. Lane, G. Thomas, The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120, 747–59 (2005)
H. Zhou, S. Huang, Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr. Protein Pept. Sci. 12, 30–42 (2011)
M.F. Crouch, Regulation of thrombin-induced stress fibre formation in swiss 3T3 cells by the 70-kDa S6 kinase. Biochem. Biophys. Res. Commun. 233, 193–9 (1997)
L.A. Berven, F.S. Willard, M.F. Crouch, Role of the p70(S6K) pathway in regulating the actin cytoskeleton and cell migration. Exp. Cell Res. 296, 183–95 (2004)
K. Sakakibara, B. Liu, S. Hollenbeck, K.C. Kent, Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am. J. Physiol. Heart Circ. Physiol. 288, H2861–H2868 (2005)
H.Y. Zhou, A.S.T. Wong, Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 147, 2557–66 (2006)
S.A. Lang, A. Gaumann, G.E. Koehl, U. Seidel, F. Bataille, D. Klein, L.M. Ellis, U. Bolder, F. Hofstaedter, H.-J. Schlitt, E.K. Geissler, O. Stoeltzing, Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int. J. Cancer 120, 1803–10 (2007)
A. Akinleye, P. Avvaru, M. Furqan, Y. Song, D. Liu, Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J. Hematol. Oncol. 6, 88 (2013)
W. Li, L. Xie, X. He, J. Li, K. Tu, L. Wei, J. Wu, Y. Guo, X. Ma, P. Zhang, Z. Pan, X. Hu, Y. Zhao, H. Xie, G. Jiang, T. Chen, J. Wang, S. Zheng, J. Cheng, D. Wan, S. Yang, Y. Li, J. Gu, Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int. J. Cancer 123, 1616–22 (2008)
E.J. Ezratty, C. Bertaux, E.E. Marcantonio, G.G. Gundersen, Clathrin mediates integrin endocytosis for focal adhesion disassembly in migrating cells. J. Cell Biol. 187, 733–47 (2009)
J.S. Desgrosellier, D.A. Cheresh, Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9–22 (2010)
H.A. Dbouk, J.M. Backer, A beta version of life: p110β takes center stage. Oncotarget 1, 729–33 (2010)
D. Kim, S. Kim, H. Koh, S.O. Yoon, A.S. Chung, K.S. Cho, J. Chung, Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 15, 1953–62 (2001)
Y.R. Chin, A. Toker, Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. Cell. Signal. 21, 470–6 (2009)
B. Brenner, M.B. Hoshen, O. Purim, M. Ben David, K. Ashkenazi, G. Marshak, Y. Kundel, R. Brenner, S. Morgenstern, M. Halpern, N. Rosenfeld, A. Chajut, Y. Niv, M. Kushnir, MicroRNAs as a potential prognostic factor in gastric cancer. World J. Gastroenterol. 17, 3976–85 (2011)
M.D. Jansson, A.H. Lund, MicroRNA and cancer. Mol. Oncol. 6, 590–610 (2012)
Acknowledgments
This study was supported by the Chilean National Fund for Scientific and Technological Development (FONDECYT NO. 1090171), the Chilean National Commission for Scientific and Technological Research (CONICYT) through a PhD scholarship and financial support for a doctoral thesis (NO. 24121456) and a Postdoctoral Scholarship from the Universidad de La Frontera.
The FV-1000 microscope experiments/data analyses were performed in part through use of the VUMC Cell Imagining Shared Resource (supported by NIH grants CA68485, DK20593, DK58404, DK59637, and EY08126).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interests.
Additional information
Ismael Riquelme and Oscar Tapia contributed equally to this work.
Rights and permissions
About this article
Cite this article
Riquelme, I., Tapia, O., Leal, P. et al. miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol. 39, 23–33 (2016). https://doi.org/10.1007/s13402-015-0247-3
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13402-015-0247-3